In an interview with The News & Observer, Dr. Barton Haynes discusses the future of HIV vaccine development after HHS ...

A new U.N. AIDS agency report says the sudden withdrawal of U.S. funding has caused a “systemic shock” to the global effort ...

The US's decision to halt most foreign aid this year has been a “systemic shock” to the fight against AIDS, according to ...

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

Until recently, the UN was on track to meet its target of ending AIDS as a public health threat by 2030. But with the U.S.

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

In a report released on Thursday, the UN body in charge of fighting HIV/Aids does not single out the US, but says that ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

It said the Uganda Aids Commission (UAC) 2024 report places the prevalence rate in Soroti City at 12.5 percent for those ...

A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...